Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (951)	11/26/1997 8:16:00 AM
From: Cw Rohart	Respond to of 2742

Good Question!

To: John Metcalf who wrote (951)	11/26/1997 2:16:00 PM
From: scaram(o)uche	Respond to of 2742

John: I was thinking of the existing motions. However, I've got better things to do with my time, and, having blown off steam, I'll just say that I won't start to contact shareholders. It's impossible, given the cash position and patents, that BlueStone won't come up with something of interest. We should give them time and see what they come up with. I'd like to think that guidance given in this thread could have an impact, but I suspect that small-thinking and/or arrogance will prevent such. Just a shame to see so much time pass with so little insight. At very least, we should try to have some attendees at the annual meeting who are willing to ask tough questions. Fortunately, I have one friend and shareholder who has already expressed an interest in doing such. Galton.... you simply take a concept (for example, tumor-targeting of inflammation) and patents and start a frigging company. It is narrow-minded, "bought into the IMNX story" thinking that has prevented you from being effective. Whack yourself on the side of the head a few times and repeat this six or seven times..... "it is not too late to use my brains." It has been obvious that you should be looking at "targeting" companies. You should look at companies that can "stealth" toxic molecules. Heck, Vical has licensed the anti-id naked DNA work from Stanford, but I'm not sure that it includes the IL-1 enhanced immunogenicity. If not, license that work!! Geeez, Galton, do something. Pick up the phone, dial it, and then talk into it. You will be amazed by what you learn. Galton, just for you....... the definition of LEARN...... to integrate a new concept.